2. Apoptosis
  3. Apoptosis
  4. Antitumor agent-115

Antitumor agent-115 (SS-12) is an effective anti-tumor compound with an IC50 value of 0.34 μM-24.14 μM for cell line 4T1. Antitumor agent-115 can block the cell cycle of mouse breast cancer cell line 4T1, reduce the mitochondrial membrane potential, and induce apoptosis, and the IC50 value is 8-25 μmol/L for cell viability. Antitumor agent-115 can be used for breast cancer research.

For research use only. We do not sell to patients.

Antitumor agent-115 Chemical Structure

Antitumor agent-115 Chemical Structure

CAS No. : 2759277-20-6

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Antitumor agent-115 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Antitumor agent-115 (SS-12) is an effective anti-tumor compound with an IC50 value of 0.34 μM-24.14 μM for cell line 4T1. Antitumor agent-115 can block the cell cycle of mouse breast cancer cell line 4T1, reduce the mitochondrial membrane potential, and induce apoptosis, and the IC50 value is 8-25 μmol/L for cell viability. Antitumor agent-115 can be used for breast cancer research[1].

In Vitro

Antitumor agent-115 (SS-12) (1.25 μM, 10 μM, 40 μM, 24h) induces 4T1 cell apoptosis primarily by arresting cell cycle at G0/G1[1].
Antitumor agent-115 (15 μM, 30 μM, 60 μM, 24h) inhibits 4T1 cell migration and invasion[1].
Antitumor agent-115 (10 μM, 24h) induces apoptosis of 4T1 cells through mitochondria pathway[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Antitumor agent-115 Related Antibodies

Cell Viability Assay[1]

Cell Line: 4T1 cell
Concentration: 1-128 μM
Incubation Time: 24, 48, 72 h
Result: Inhibited 4T1 cells proliferation with IC50 value of 8-25 μM.

Apoptosis Analysis[1]

Cell Line: 4T1 cell
Concentration: 1.25 μM, 10 μM, 40 μM
Incubation Time: 24 h
Result: Increased apoptosis rates of 4T1 cell at concentration of 1.25 μM.

Cell Cycle Analysis[1]

Cell Line: 4T1 cell
Concentration: 1.25 μM, 10 μM, 40 μM
Incubation Time: 24 h
Result: Increased the proportion in the G0/G1 phase and decreased in the S and G2/M phases of 4T1 cells.

Cell Migration Assay [1]

Cell Line: 4T1 cell
Concentration: 15 μM, 30 μM, 60 μM
Incubation Time: 24 h
Result: Expanded the wound area and inhibited cell migration and invasion at concentration of 0.03 μM.

Western Blot Analysis[1]

Cell Line: 4T1 cell
Concentration: 10 μM
Incubation Time: 24 h
Result: Improved the cleaved caspase-3 expression and and Bax expression, but inhibited the anti-apoptosis protein Bcl2 expression in 4T1 cells.
In Vivo

Antitumor agent-115 (SS-12) (10 mg stachydrine/kg equivale, 200 μL for Oral administration) has greater bioavailability in rats[1].
Antitumor agent-115 (0.2 mmol/kg for Oral administration) has anti-tumor effects in breast cancer model mice and improves morphological structure of spleen in model mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Rats[1]
Dosage: 10 mg stachydrine/kg equivale, 200 μL
Administration: Oral administration (p. o.)
Result: Exhibited high systemic exposure with 6.10 μg/mL of Cmax value and 14.75 h μg/mL of AUC0-t value.
Animal Model: Tumor-bearing mice[1]
Dosage: 0.2 mmol/kg
Administration: Oral administration (p. o.)
Result: Inhibitory rate was 51.47% ( P < 0.01)
Displayed significant tumor cell shrinkage and larger void areas in tumor tissues
Exhibited more weight loss than the model group and other treatment groups, increased of both AST and ALT levels and reduced spleen index of the tumor-bearing mice
Molecular Weight

347.96

Formula

C19H38ClNO2
CAS No.
SMILES

C[N+]1(C)C(C(OCCCCCCCCCCCC)=O)CCC1.[Cl-]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Antitumor agent-115 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Antitumor agent-1152759277-20-6Antitumor agent115Antitumor agent 115Apoptosisstachydrinebreast cancerbioavailability4T1Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Antitumor agent-115
Cat. No.:
HY-155745
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.